Burning Rock Biotech
BNR
47 hedge funds and large institutions have $426M invested in Burning Rock Biotech in 2020 Q2 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.87% more ownership
Funds ownership: 0% → 1.87% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$130M |
| 2 |
MICM
Matthews International Capital Management
San Francisco,
California
|
+$49.7M |
| 3 |
CC
Casdin Capital
New York
|
+$47.4M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$23.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$21.6M |
Top Sellers
BNR Hedge Fund Activity: Q2 2020 in Review
47 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q2 2020, worth a combined $426M.
Buyers outnumbered sellers: 47 funds opened new BNR positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $130M.
- 47 institutional investors held Burning Rock Biotech (BNR) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $426M of Burning Rock Biotech stock for Q2 2020.
- 47 funds opened new Burning Rock Biotech positions in Q2 2020 and 0 closed out, a net change of +47 holders.
- The largest Burning Rock Biotech buyer in Q2 2020 was OrbiMed, an estimated $130M added.
Based on aggregated 13F filings for Q2 2020.